The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
Authors:
- SAIS Study GroupSGSAIS Study Group
- Naoyuki KitaoNKNaoyuki Kitao
- Hideaki MiyoshiHMHideaki Miyoshi
- Tomoo FurumotoTFTomoo Furumoto
- Kota OnoKOKota Ono
- Hiroshi NomotoHNHiroshi Nomoto
- Aika MiyaAMAika Miya
- Chiho YamamotoCYChiho Yamamoto
- Atsushi InoueAIAtsushi Inoue
- Kenichi TsuchidaKTKenichi Tsuchida
- Naoki MandaNMNaoki Manda
- Yoshio KuriharaYKYoshio Kurihara
Open Access
- 10 October 2017
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 125
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown in recent randomized placebo-controlled studies. Therefore, we investigated the efficacy of DPP-4 inhibitor on endothelial function and glycemic metabolism compared with high-dose metformin. In this multicenter, open-labeled, prospective, randomized, parallel-group comparison study, patients with type 2 diabetes treated with low-dose metformin (500–750 mg/day) were enrolled and randomly assigned to a vildagliptin, a DPP-4 inhibitor, add-on group (Vilda) or a double dose of metformin group (high Met) for 12 weeks. Flow-mediated dilation (FMD) and serum metabolic markers were assessed before and after treatment. In addition, glycemic control and metabolic parameters were also assessed. Ninety-seven subjects (aged 58.7 ± 11.0 years; body mass index, 25.9 ± 4.4 kg/m2; HbA1c, 7.3 ± 0.5%; FMD, 5.8 ± 2.6%) were enrolled. Eight subjects dropped out by the end of the study. There were no significant differences between the two groups in baseline characteristics. After 12 weeks, HbA1c was significantly improved in the Vilda group compared with the high Met group (− 0.80 ± 0.38% vs. − 0.40 ± 0.47%, respectively; p < 0.01). However, there were no significant differences in FMD (− 0.51 [− 1.08–0.06]% vs. − 0.58 [− 1.20–0.04]%). Although the apolipoprotein B/apolipoprotein A1 ratio was significantly reduced in the Vilda group compared with baseline (0.66–0.62; p < 0.01), the change did not differ significantly between the two groups (− 0.04 vs. 0.00; p = 0.27). Adiponectin levels were significantly increased in the Vilda group compared with the high Met group (0.75 μg/mL vs. 0.01 μg/mL; p < 0.01). Regardless of glycemic improvement, combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile in patients with type 2 diabetes without advanced atherosclerosis.Keywords
Funding Information
- Hokkaido Diabetes Clinical Research Organization
This publication has 71 references indexed in Scilit:
- Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetesCardiovascular Diabetology, 2013
- Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic PatientsJournal of the American Heart Association, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 DiabetesJournal of Korean Medical Science, 2012
- Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experienceVascular Health and Risk Management, 2010
- Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular riskVascular Health and Risk Management, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes MedicationsArchives of internal medicine (1960), 2008
- Central Pressure More Strongly Relates to Vascular Disease and Outcome Than Does Brachial PressureHypertension, 2007
- Metformin Inhibits Cytokine-Induced Nuclear Factor κB Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial CellsHypertension, 2006
- Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous interventionThe American Journal of Cardiology, 2004